TG ImmunoPharma (TGI)
TG ImmunoPharma (TGI),
established in 2021, is a clinical-stage biotech company dedicated to developing innovative immunotherapies for cancer and autoimmune diseases. In just four years, TGI has built a robust pipeline of eight cutting-edge programs, including antibodies, multi-specific antibodies, and NK cell engagers, with three assets receiving IND clearances in both the U.S. and China. Its lead candidate, TGI-6, a B7H6 x CD3 bispecific antibody, is currently in Phase 1 clinical trials and is one of only two B7H6-targeted therapies globally in clinical development. TGI’s proprietary platforms, such as the pH-selective TCE platform and ABC-NKer platform, are designed to enhance the safety and efficacy of immunotherapies, addressing unmet medical needs in solid tumors and autoimmune diseases.
Shenzhen AntiV Pharma
Shenzhen AntiV Pharma,
Founded on August 23, 2021, in Pingshan District, Shenzhen, AntiV is a biopharmaceutical company specializing in the research and development of antiviral drugs. Its primary areas of focus include diseases caused by coronaviruses, human immunodeficiency viruses (HIV), hepatitis viruses, and others. Among the company's projects, the small-molecule oral antiviral drug SHEN26 for COVID-19 has completed Phase III clinical trials. Additionally, the company is developing treatments for monkeypox, influenza, and veterinary applications. AntiV has applied and owned 41 patents (including 8 under the PCT system) and has been granted 10 patents. The company's R&D efforts have received substantial support from national, provincial, and municipal governments. Since its establishment, AntiV has received multiple technological awards and honors, including recognition as a National High-Tech Enterprise, a "Specialized and Innovative" SME (Small and Medium-sized Enterprise), an Innovative SME and a National-Level Technology-Based SME.
TYK Medicines, Inc
TYK Medicines, Inc.
was established in November 2017 in Life Science Park Changxing Economic Development Zone with a fully functionalized 30,000 square meters world-class drug discovery R&D center; subsequently, the company set up the administrative headquarters, medical affairs, and business development in Shanghai. In Zhengzhou, the company has its small molecule drug screening platform. In addition to the current scope, the company is building DP plants in Changxing, Zhejiang Province, and Songjiang District, Shanghai. Thus, the company is capable of a whole industry chain of innovative drug discoveries, as well as drug manufacturing, which makes the company the first-tier innovative biotechnology company in China.
Immunowake
Immunowake
is an early-stage biotech company focused on creating targeted immunocytokines for the treatment of oncology and autoimmune diseases through our proprietary platforms. Our strategy is to wake up the patient’s immune system to recognize and kill cancer cells. Hence, the name Immunowake. Next generation immuno-oncology is focused on generating agonists that can activate the immune system. Our oncology pipeline is targeted towards patients with advanced malignant tumors and patients who have failed PD1/PDL1 blockade. We utilize cis-targeting to deliver cytokines to tumor infiltrating lymphocytes (TILs), which specifically activates anti-tumor immune responses. The use of attenuated cytokines further reduces cytokine sink and cytokine-mediated toxicities, resulting in increased safety profiles of our molecules. Our autoimmune disease pipeline is focused on boosting the Treg immune inhibition, while avoiding further stimulation of activated effector CD8 and NK cells. Immunowake was founded in Delaware, USA. We have R&D laboratories located in Shanghai, China and Birmingham, Alabama. Since 2022, we have raised $20 million Series A capital. Immunowake brings scientific discoveries from both China and the United States to develop novel therapies for cancer and autoimmune diseases. Immunowake is an early-stage biotech company focused on creating targeted immunocytokines for the treatment of oncology and autoimmune diseases through our proprietary platforms. Our strategy is to wake up the patient’s immune system to recognize and kill cancer cells. Hence, the name Immunowake. Next generation immuno-oncology is focused on generating agonists that can activate the immune system. Our oncology pipeline is targeted towards patients with advanced malignant tumors and patients who have failed PD1/PDL1 blockade. We utilize cis-targeting to deliver cytokines to tumor infiltrating lymphocytes (TILs), which specifically activates anti-tumor immune responses. The use of attenuated cytokines further reduces cytokine sink and cytokine-mediated toxicities, resulting in increased safety profiles of our molecules. Our autoimmune disease pipeline is focused on boosting the Treg immune inhibition, while avoiding further stimulation of activated effector CD8 and NK cells. Immunowake was founded in Delaware, USA. We have R&D laboratories located in Shanghai, China and Birmingham, Alabama. Since 2022, we have raised $20 million Series A capital. Immunowake brings scientific discoveries from both China and the United States to develop novel therapies for cancer and autoimmune diseases.
